"The study recruited 30 patients with newly diagnosed glioblastoma and unmethylated MGMT promotor status, a genetic profile which confers primary resistance to temozolomide, the only existing FDA-approved drug treatment for first line treatment."
KZA Price at posting:
$1.42 Sentiment: Buy Disclosure: Held